<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="533">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521400</url>
  </required_header>
  <id_info>
    <org_study_id>Interferon in COVID</org_study_id>
    <nct_id>NCT04521400</nct_id>
  </id_info>
  <brief_title>the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19</brief_title>
  <official_title>the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a randomized clinical trial, with the approval of the ethics committee
      will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim
      Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the
      study and after completing the course of treatment and collecting and analyzing the necessary
      information from each patient, the results of the study will be published both on this site
      and in the form of an article in a reputable international journal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to previous studies, IFN-β has strong antiviral activity and also has an acceptable
      safety profile. Based on possible therapeutic effects, we decided to lead an Investigation
      into Beneficial Effects of high-dose Interferon Beta 1a, Compared to low-dose Interferon Beta
      1a (the base therapeutic regimen) in Moderate to Severe COVID-19.

      Previous studies demonstrate that IFN-β 1a could be used against some coronaviruses including
      avium infectious, bronchitis virus, murine hepatitis virus, and SARS- CoV because they are
      susceptible in vitro or in vivo. In a current study, the efficacy of IFN-β 1a in COVID-19
      patients were evaluated, and they found than IFN-β 1a reduced the disease symptoms.

      The present study is a randomized clinical trial, with the approval of the ethics committee
      will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim
      Medical Education Center in Tehran.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2020</start_date>
  <completion_date type="Anticipated">September 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>From date of randomization until 14 days later</time_frame>
    <description>Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From date of randomization until 14 days later</time_frame>
    <description>If the patient dies, we have reached an outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2 Improvement</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 6, 7 and 14</time_frame>
    <description>Pulse-oxymetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new mechanical ventilation use</measure>
    <time_frame>From date of randomization until 14 days later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of serious adverse events</measure>
    <time_frame>Days 1, 2, 3, 4, 5, 6, 7 and 14</time_frame>
    <description>With the incidence of any serious adverse effects, the outcome has happened</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir /Ritonavir +high dose Interferon-β 1a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir /Ritonavir + Low dose Interferon-β 1a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Interferon-beta 1a</intervention_name>
    <description>High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)</description>
    <arm_group_label>Arm1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>Lopinavir/Ritonavir (Kaletra) [IFN-β1a group] (400mg/100 mg twice a day for 10 days</description>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Interferon-beta 1a</intervention_name>
    <description>Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)</description>
    <arm_group_label>Arm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed)

          -  at least one of the following: radiation contactless body temperature ≥37.5, cough,
             shortness of breath, nasal congestion/ discharge, myalgia/arthralgia,
             diarrhea/vomiting, headache or fatigue on admission.

          -  Time of onset of the symptoms should be acute (Days ≤ 14)

          -  NEWS2 ≥ 1 on admission (National Early Warning Score 2)

        Exclusion Criteria:

          -  Refusal to participate expressed by patient or legally authorized representative if
             they are present

          -  Patients using drugs with potential interaction with Lopinavir/Ritonavir or
             Interferon-β 1a

          -  Pregnant or lactating women.

          -  History of alcohol or drug addiction in the past 5 years.

          -  Blood ALT/AST levels &gt; 5 times the upper limit of normal on laboratory results.

          -  The patients who were intubated less than one hours after admission to the hospital
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilad Alavi Darazam, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Firouze Hatami, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Mahdi Rabiei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omid Moradi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Behnam Rahimi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shervin Shokouhi, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Reza Hajesmaeili, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minoosh Shabani, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyed Sina Naghibi Irvani, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilad Alavi Darazam, MD</last_name>
    <phone>+98-914-149-1958</phone>
    <email>ilad13@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.</citation>
    <PMID>32132184</PMID>
  </reference>
  <reference>
    <citation>Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.</citation>
    <PMID>32221306</PMID>
  </reference>
  <reference>
    <citation>Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, Dong XQ, Zheng YT. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):541-543. doi: 10.1038/s41423-020-0401-3. Epub 2020 Mar 17.</citation>
    <PMID>32203186</PMID>
  </reference>
  <reference>
    <citation>Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol. 2019 Jun;43:101300. doi: 10.1016/j.smim.2019.101300. Review.</citation>
    <PMID>31771760</PMID>
  </reference>
  <reference>
    <citation>Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.</citation>
    <PMID>32401715</PMID>
  </reference>
  <reference>
    <citation>Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis. 2004 Feb;10(2):317-9.</citation>
    <PMID>15030704</PMID>
  </reference>
  <reference>
    <citation>Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, Hashemian SM, Baghaei P, Abedini A, Varahram M, Yousefian S, Tabarsi P. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug;85:106688. doi: 10.1016/j.intimp.2020.106688. Epub 2020 Jun 7.</citation>
    <PMID>32544867</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ilad Alavi Darazam</investigator_full_name>
    <investigator_title>Dr. Ilad Alavi Darazam, MD</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Interferons</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Lopinavir</keyword>
  <keyword>Interferon-beta</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Immunologic Factors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

